Silexion Therapeutics (NASDAQ: SLXN) has completed preclinical studies of its RNAi therapeutic candidate, SIL204, in colorectal, lung, and pancreatic cancer cell lines with KRAS mutations. The company plans to release detailed results soon. These studies build on Silexion’s existing pancreatic cancer focus and expand the potential application of SIL204 to address a combined market estimated at over $30 billion annually.
This expansion into other KRAS-driven cancers is crucial because KRAS mutations are prevalent drivers in several difficult-to-treat cancers. Current treatments using small molecules or antibodies struggle to effectively target most KRAS variants. Positive results for SIL204 could validate Silexion’s RNAi approach as a viable alternative, potentially revolutionizing treatment options and addressing this substantial unmet medical need.
SIL204 was tested against cell lines representing colorectal cancer (GP2D), lung cancer (A427), and pancreatic cancer (Panc-1), chosen for their high KRAS mutation rates. This research follows Silexion’s Phase 2 trial of LODER™ for non-resectable pancreatic cancer.
Positive results from this preclinical study could significantly broaden SIL204’s development pathway and position Silexion to address a larger market of KRAS-driven cancers. This would represent a significant advancement in Silexion’s pipeline and potentially lead to new, more effective treatment options for patients with these challenging cancers.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
